Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro

Journal of Immunotherapy

Volumn 21, Issue 2, 1998, Pages 149-157

  Tjandrawan, Tjendimin ^a   Martin, Dina M ^a   Maeurer, Markus J ^b   Castelli, Chiara ^c   Lotze, Michael T ^a   Storkus, Walter J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Dendritic cells Tumor peptides; Melanoma; Natural peptides; Vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANTIGENS, NEOPLASM; CELL DIVISION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN-4; MELANOMA; PEPTIDES; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0031936881     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Storkus WJ, Lotze MT. Biology of tumor antigens: tumor antigens recognized by immune cells. In: DeVita V, Hellman S, Rosenberg S, eds. Biologic therapy of cancer. 2nd ed. Philadelphia: Lippincott, 1995:64-77.
2. Bodmer W. T-cell immune responses to cancer - a new look. Hum Immunol 1991;30:259-67.
3. Melief CJM, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv 1992;13:81-99.
4. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
5. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumor immunity. Nature Med 1995;1: 1297-302.
6. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-8.
7. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-10.
8. Porgador A, Gilboa E. Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255-60.
9. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
10. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide pulsed dependence on T-cells, B7 costimulation, and Th1-associated cytokines. J Exp Med 1996;183: 87-98.
11. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-5.
12. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J Exp Med 1996;183:317-22.
13. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
14. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
15. Bakker AB, Marland G, De Boer AJ, Danen H, Adema GJ, Figdor CG. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55: 5330-9.
16. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995;55:1099-104.
17. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 1993;53:5-8.
18. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
19. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
20. Storkus WJ, Zeh HJ III, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993;151: 3719-27.
21. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
22. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-34.
23. Mosialos G, Birkenbach M, Ayehunie S, et al. Circulating human dendritic cells differentially express high levels of a 55 kD actin-bundling protein. Am J Pathol 1996;148:593-600.
24. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukocyte Biol 1996;59:208-18.
25. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-5.
26. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.